Filing Date |
T Date |
Ticker |
Sector |
Ind | Industry |
Owner |
oSt |
Rel |
Title |
#f |
T |
TVal |
Price |
L |
Qty |
oc |
Own |
H |
r2y |
r1y |
r6m |
r3m |
r6w |
r3w |
r7d |
r3d |
f1d |
f1w |
f1m |
f3m |
f6m |
f1y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
7/27/26 16:08 | 7/23/26 | IRD | Health | Drug | Pharmaceutical Preparations | Yerxa Benjamin R | NC | DO | P | 1 | S | -22 | 2.97 | 0 | -7 | 704 | D | |||||||||||||||
7/27/26 16:07 | 7/23/26 | IRD | Health | Drug | Pharmaceutical Preparations | Schachle Joseph K | NC | O | COO | 1 | S | -14 | 2.94 | 0 | -5 | 291 | D | |||||||||||||||
7/27/26 16:07 | 7/23/26 | IRD | Health | Drug | Pharmaceutical Preparations | Magrath George | NC | DO | CEO | 1 | S | -28 | 2.95 | 0 | -9 | 1,732 | D | |||||||||||||||
7/27/26 16:06 | 7/23/26 | IRD | Health | Drug | Pharmaceutical Preparations | Gagnon Robert E. | NC | O | CFO | 1 | S | -23 | 2.95 | 0 | -8 | 584 | D | |||||||||||||||
5/20/26 19:29 | 5/18/26 | IRD | Health | Drug | Pharmaceutical Preparations | Foundation Fighting Blindness Retinal Degeneration Fund | NC | DH | See Rema | 1 | S | -7,395 | 4.35 | 0 | -1,700 | 3,792 | D |
| D | Derivative transaction in filing (usually option exercise) |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| A | Amended filing |
| E | Error detected in filing |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |